BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 21, 2008
View Archived Issues
Presidio Gains Early Hepatitis C Program from XTL in $108M Deal
Small antiviral firm Presidio Pharmaceuticals Inc. picked up rights to a group of preclinical small molecules targeting hepatitis C virus in a potential $108 million deal with XTL Biopharmaceuticals Ltd. (BioWorld Today)
Read More
Cephalon Gets Much-Anticipated Nod for Treanda in CLL Patients
Read More
New Herpes Co-Receptor Found in Research Study
Read More
EPIX Cancels Depression Drug Following Phase IIb Failure
Read More
PharmAthene Buys Vaccines from Avecia in $40M Deal
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Financings Roundup
Read More